SCH 54031
Hepatitis
Merck Sharp & Dohme LLCPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Hepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MIDAZOLAM Erasme University Hospital | Phase 4 | BB |
Meperidine Erasme University Hospital | Phase 4 | BB |
Orlistat St. Louis University | Phase 4 | BB |
URSODEOXYCHOLIC ACID West China Hospital | Phase 4 | BB |
Diammonium Glycyrrhizinate Cttq | Phase 4 | BB |
View all 31 →
Same molecule, other indications
SCH 54031 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →